Abstract
Aim: Helicobacter pyloriinfection is a prevalent global bacterial infection that can potentially exaggerate symptoms of other serious infections like SARS-CoV-2 (COVID-19). Methodology: Herein, an efficient, accurate and cost-effectivehigh-performance liquid chromatography-diode array detectormethod was developed and validated for determination of the novel triple therapy combination of tinidazole (TD), clarithromycin (CLR) and lansoprazole (LAN) in different analytical matrices (pharmaceutical formulation, dissolution media and spiked human plasma). Results: Successful chromatographic separation was achieved using Agilent Microsorb-MV 100-5 CN column (250×4.6mm, 5μm) and a mobile phase consisted of acetonitrile and 10.0mM phosphate buffer, pH 7.5±0.1 at flow rate of 1ml/min via gradient elution. UV-detection was accomplished at 210.0nm for CLR and 290.0nm for TD and LAN. Conclusion: The developed method clearly provides a reliable, beneficial and cost-effective tool for quality control, dissolution testing and biological applications of the mentioned drugs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
